Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT03539536




Registration number
NCT03539536
Ethics application status
Date submitted
17/05/2018
Date registered
29/05/2018
Date last updated
19/01/2024

Titles & IDs
Public title
Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer
Scientific title
Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects With Previously Treated c-Met+ Non-Small Cell Lung Cancer
Secondary ID [1] 0 0
2023-507902-15-00
Secondary ID [2] 0 0
M14-239
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Non-small Cell Lung Cancer 0 0
Condition category
Condition code
Cancer 0 0 0 0
Lung - Mesothelioma
Cancer 0 0 0 0
Lung - Non small cell
Cancer 0 0 0 0
Lung - Small cell

Intervention/exposure
Study type
Interventional(has expanded access)
Description of intervention(s) / exposure
Treatment: Drugs - Telisotuzumab vedotin

Experimental: Telisotuzumab vedotin - Telisotuzumab vedotin administered via intravenous (IV) infusion every 14 days.


Treatment: Drugs: Telisotuzumab vedotin
Intravenous (IV) infusion
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Overall Response Rate (ORR) (Stage 1 and Stage 2)
Timepoint [1] 0 0
Up to approximately 3 years
Primary outcome [2] 0 0
Number of Participants with Adverse Events (Alternate dose cohort)
Timepoint [2] 0 0
Up to approximately 3 years
Secondary outcome [1] 0 0
Duration of Response (DoR) (Stage 1 and Stage 2)
Timepoint [1] 0 0
Up to approximately 3 years
Secondary outcome [2] 0 0
Disease Control Rate (DCR) (Stage 1 and Stage 2)
Timepoint [2] 0 0
Up to approximately 3 years
Secondary outcome [3] 0 0
Progression-Free Survival (PFS) (Stage 1 and Stage 2)
Timepoint [3] 0 0
Up to approximately 3 years
Secondary outcome [4] 0 0
Overall Survival (OS) (Stage 1 and Stage 2)
Timepoint [4] 0 0
Up to approximately 3 years

Eligibility
Key inclusion criteria
- Have locally advanced or metastatic non-small cell lung cancer (NSCLC).

- Have c-Met+ NSCLC as assessed by an AbbVie designated immunohistochemistry (IHC)
laboratory. Participant must submit archival or fresh tumor material for assessment of
c-Met levels during the prescreening period. Tumor material from the primary tumor
site and/or metastatic sites are allowed. If archival tissue is negative for c-Met
overexpression, subject can submit fresh biopsy material for reassessment of c-Met
expression.

- Histologically documented non-squamous epidermal growth factor receptor (EGFR) wild
type NSCLC (site documented EGFR status). Of note, subjects with other actionable
mutations are eligible as long as EGFR status is known and all other eligibility
criteria are met. As of Protocol Version 11, Stage 1 is complete and Stage 2 is
enrolling participants with non-squamous EGFR wild type NSCLC only.

- Must have received no more than 2 lines of prior systemic therapy (including no more
than 1 line of systemic cytotoxic chemotherapy) in the locally advanced or metastatic
setting.

- Multiple lines of tyrosine kinase inhibitors (TKIs) targeting the same tyrosine kinase
(TK) count as 1 line of therapy for the purposes of this eligibility criterion.

- Progressed on systemic cytotoxic therapy (or are ineligible for systemic cytotoxic
chemotherapy) and an immune checkpoint inhibitor (as monotherapy or in combination
with systemic cytotoxic chemotherapy, or ineligible), and prior anticancer therapies
targeting driver gene alterations (if applicable).

- Have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1.

- Treatment with any therapies within the noted time intervals is excluded prior to the
first dose of telisotuzumab vedotin as noted in the protocol.

- Metastases to the central nervous system (CNS) are eligible only after definitive
therapy (such as surgery or radiotherapy) is provided within the protocol.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Have received radiation therapy to the lungs < 6 months prior to the first dose of
telisotuzumab vedotin.

- Have received any live vaccine within 30 days of the first dose of investigational
product.

- Has adenosquamous histology.

- Have a history of other malignancies except those noted within the protocol.

- Have a history of interstitial lung disease (ILD) or pneumonitis that required
treatment with systemic steroids.

- Have any evidence of pulmonary fibrosis on screening imaging assessment or any history
of pneumonitis or ILD within 3 months of the planned first dose of the study drug
(Except for Sites in Ireland). For imaging findings deemed clinically insignificant by
the treating physician, subject may be eligible after discussion with and approval
from the AbbVie medical monitor.

- For Sites in Ireland Only: Must not have any evidence of pulmonary fibrosis on
screening imaging assessment or any history of pneumonitis or ILD. For imaging
findings deemed clinically insignificant by the treating physician, subject may be
eligible after discussion with and approval from the AbbVie medical monitor.

- Have a clinically significant condition(s) as noted in the protocol.

- Have unresolved clinically significant adverse events of Grade >= 2 from prior
anticancer therapy, except for alopecia or anemia.

- Have had major surgery within 21 days prior to the first dose of telisotuzumab
vedotin.

- For Sites in France and Czech Republic Only: Have the following:

- Known human immunodeficiency virus (HIV) infection. Note: HIV testing is not
required for eligibility for this protocol unless mandated by local regulatory
authority or ethics committee/institutional review board.

- Active hepatitis B virus (HBV) infection, defined by hepatitis B surface antigen
(HBsAg) positivity or HBV DNA >= 500 IU/mL. In participants with known HBV
infection, the presence of active infection must be tested locally. If HBV status
is unknown, it must be tested locally at screening.

- Active hepatitis C virus (HCV) infection, defined by HCV ribonucleic acid (RNA)
positivity. Participants cured of HCV infection may be included in the study. In
participants with known HCV infection, the presence of active infection must be
tested locally. If HCV status is unknown, it must be tested locally at screening.

- Uncontrolled autoimmune disease.

Study design
Purpose of the study
Treatment
Allocation to intervention
N/A
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
10/10/2018
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
6/10/2025
Actual
Sample size
Target
Accrual to date
Final
270
Recruitment in Australia
Recruitment state(s)
NSW,QLD,WA
Recruitment hospital [1] 0 0
The Kinghorn Cancer Centre /ID# 207666 - Darlinghurst
Recruitment hospital [2] 0 0
Newcastle Private Hospital /ID# 206600 - Lambton Heights
Recruitment hospital [3] 0 0
The Tweed Hospital /ID# 206601 - Tweed Heads
Recruitment hospital [4] 0 0
Mater Misericordiae Limited /ID# 229639 - South Brisbane
Recruitment hospital [5] 0 0
St John Of God Subiaco Hospital /ID# 226943 - Subiaco
Recruitment postcode(s) [1] 0 0
2010 - Darlinghurst
Recruitment postcode(s) [2] 0 0
2305 - Lambton Heights
Recruitment postcode(s) [3] 0 0
2485 - Tweed Heads
Recruitment postcode(s) [4] 0 0
4101 - South Brisbane
Recruitment postcode(s) [5] 0 0
6008 - Subiaco
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
Arkansas
Country [4] 0 0
United States of America
State/province [4] 0 0
California
Country [5] 0 0
United States of America
State/province [5] 0 0
Colorado
Country [6] 0 0
United States of America
State/province [6] 0 0
Florida
Country [7] 0 0
United States of America
State/province [7] 0 0
Hawaii
Country [8] 0 0
United States of America
State/province [8] 0 0
Illinois
Country [9] 0 0
United States of America
State/province [9] 0 0
Indiana
Country [10] 0 0
United States of America
State/province [10] 0 0
Kansas
Country [11] 0 0
United States of America
State/province [11] 0 0
Kentucky
Country [12] 0 0
United States of America
State/province [12] 0 0
Maine
Country [13] 0 0
United States of America
State/province [13] 0 0
Massachusetts
Country [14] 0 0
United States of America
State/province [14] 0 0
Michigan
Country [15] 0 0
United States of America
State/province [15] 0 0
Minnesota
Country [16] 0 0
United States of America
State/province [16] 0 0
Mississippi
Country [17] 0 0
United States of America
State/province [17] 0 0
Missouri
Country [18] 0 0
United States of America
State/province [18] 0 0
Montana
Country [19] 0 0
United States of America
State/province [19] 0 0
New Hampshire
Country [20] 0 0
United States of America
State/province [20] 0 0
New Jersey
Country [21] 0 0
United States of America
State/province [21] 0 0
New Mexico
Country [22] 0 0
United States of America
State/province [22] 0 0
Ohio
Country [23] 0 0
United States of America
State/province [23] 0 0
Oklahoma
Country [24] 0 0
United States of America
State/province [24] 0 0
Oregon
Country [25] 0 0
United States of America
State/province [25] 0 0
Pennsylvania
Country [26] 0 0
United States of America
State/province [26] 0 0
Tennessee
Country [27] 0 0
United States of America
State/province [27] 0 0
Texas
Country [28] 0 0
United States of America
State/province [28] 0 0
Virginia
Country [29] 0 0
United States of America
State/province [29] 0 0
Washington
Country [30] 0 0
United States of America
State/province [30] 0 0
Wisconsin
Country [31] 0 0
Belgium
State/province [31] 0 0
Antwerpen
Country [32] 0 0
Belgium
State/province [32] 0 0
Hainaut
Country [33] 0 0
Belgium
State/province [33] 0 0
Oost-Vlaanderen
Country [34] 0 0
Belgium
State/province [34] 0 0
Anderlecht
Country [35] 0 0
Belgium
State/province [35] 0 0
Gent
Country [36] 0 0
Belgium
State/province [36] 0 0
Hasselt
Country [37] 0 0
Belgium
State/province [37] 0 0
Kortrijk
Country [38] 0 0
Belgium
State/province [38] 0 0
Liege
Country [39] 0 0
Belgium
State/province [39] 0 0
Namur
Country [40] 0 0
Bulgaria
State/province [40] 0 0
Dobrich
Country [41] 0 0
Bulgaria
State/province [41] 0 0
Pleven
Country [42] 0 0
Bulgaria
State/province [42] 0 0
Sofia
Country [43] 0 0
Canada
State/province [43] 0 0
Alberta
Country [44] 0 0
Canada
State/province [44] 0 0
Ontario
Country [45] 0 0
Canada
State/province [45] 0 0
Quebec
Country [46] 0 0
China
State/province [46] 0 0
Anhui
Country [47] 0 0
China
State/province [47] 0 0
Beijing
Country [48] 0 0
China
State/province [48] 0 0
Fujian
Country [49] 0 0
China
State/province [49] 0 0
Guangdong
Country [50] 0 0
China
State/province [50] 0 0
Guangxi
Country [51] 0 0
China
State/province [51] 0 0
Hebei
Country [52] 0 0
China
State/province [52] 0 0
Heilongjiang
Country [53] 0 0
China
State/province [53] 0 0
Henan
Country [54] 0 0
China
State/province [54] 0 0
Hubei
Country [55] 0 0
China
State/province [55] 0 0
Jiangsu
Country [56] 0 0
China
State/province [56] 0 0
Jilin
Country [57] 0 0
China
State/province [57] 0 0
Shandong
Country [58] 0 0
China
State/province [58] 0 0
Shanghai
Country [59] 0 0
China
State/province [59] 0 0
Sichuan
Country [60] 0 0
China
State/province [60] 0 0
Xinjiang
Country [61] 0 0
China
State/province [61] 0 0
Zhejiang
Country [62] 0 0
Czechia
State/province [62] 0 0
Praha
Country [63] 0 0
France
State/province [63] 0 0
Bouches-du-Rhone
Country [64] 0 0
France
State/province [64] 0 0
Gironde
Country [65] 0 0
France
State/province [65] 0 0
Hauts-de-France
Country [66] 0 0
France
State/province [66] 0 0
Paris
Country [67] 0 0
France
State/province [67] 0 0
Rhone
Country [68] 0 0
France
State/province [68] 0 0
Val-de-Marne
Country [69] 0 0
France
State/province [69] 0 0
Strasbourg cedex
Country [70] 0 0
France
State/province [70] 0 0
Toulon
Country [71] 0 0
Germany
State/province [71] 0 0
Baden-Wuerttemberg
Country [72] 0 0
Germany
State/province [72] 0 0
Bayern
Country [73] 0 0
Germany
State/province [73] 0 0
Hessen
Country [74] 0 0
Germany
State/province [74] 0 0
Sachsen-Anhalt
Country [75] 0 0
Germany
State/province [75] 0 0
Berlin
Country [76] 0 0
Germany
State/province [76] 0 0
Gauting
Country [77] 0 0
Germany
State/province [77] 0 0
Hamm
Country [78] 0 0
Germany
State/province [78] 0 0
Kassel
Country [79] 0 0
Germany
State/province [79] 0 0
Oldenburg
Country [80] 0 0
Greece
State/province [80] 0 0
Attiki
Country [81] 0 0
Greece
State/province [81] 0 0
Kriti
Country [82] 0 0
Greece
State/province [82] 0 0
Thessaloniki
Country [83] 0 0
Hungary
State/province [83] 0 0
Borsod-Abauj-Zemplen
Country [84] 0 0
Hungary
State/province [84] 0 0
Pest
Country [85] 0 0
Hungary
State/province [85] 0 0
Budapest
Country [86] 0 0
Hungary
State/province [86] 0 0
Farkasgyepu
Country [87] 0 0
Hungary
State/province [87] 0 0
Matrahaza
Country [88] 0 0
Ireland
State/province [88] 0 0
Cork
Country [89] 0 0
Ireland
State/province [89] 0 0
Dublin
Country [90] 0 0
Israel
State/province [90] 0 0
H_efa
Country [91] 0 0
Israel
State/province [91] 0 0
HaDarom
Country [92] 0 0
Israel
State/province [92] 0 0
HaMerkaz
Country [93] 0 0
Israel
State/province [93] 0 0
Tel-Aviv
Country [94] 0 0
Italy
State/province [94] 0 0
Milano
Country [95] 0 0
Italy
State/province [95] 0 0
Roma
Country [96] 0 0
Italy
State/province [96] 0 0
Torino
Country [97] 0 0
Italy
State/province [97] 0 0
Avellino
Country [98] 0 0
Italy
State/province [98] 0 0
Bologna
Country [99] 0 0
Italy
State/province [99] 0 0
Meldola
Country [100] 0 0
Italy
State/province [100] 0 0
Napoli
Country [101] 0 0
Italy
State/province [101] 0 0
Parma
Country [102] 0 0
Italy
State/province [102] 0 0
Rome
Country [103] 0 0
Japan
State/province [103] 0 0
Aichi
Country [104] 0 0
Japan
State/province [104] 0 0
Aomori
Country [105] 0 0
Japan
State/province [105] 0 0
Chiba
Country [106] 0 0
Japan
State/province [106] 0 0
Ehime
Country [107] 0 0
Japan
State/province [107] 0 0
Fukuoka
Country [108] 0 0
Japan
State/province [108] 0 0
Hiroshima
Country [109] 0 0
Japan
State/province [109] 0 0
Hyogo
Country [110] 0 0
Japan
State/province [110] 0 0
Kanagawa
Country [111] 0 0
Japan
State/province [111] 0 0
Mie
Country [112] 0 0
Japan
State/province [112] 0 0
Miyagi
Country [113] 0 0
Japan
State/province [113] 0 0
Niigata
Country [114] 0 0
Japan
State/province [114] 0 0
Okayama
Country [115] 0 0
Japan
State/province [115] 0 0
Osaka
Country [116] 0 0
Japan
State/province [116] 0 0
Saitama
Country [117] 0 0
Japan
State/province [117] 0 0
Shizuoka
Country [118] 0 0
Japan
State/province [118] 0 0
Tokyo
Country [119] 0 0
Japan
State/province [119] 0 0
Yamaguchi
Country [120] 0 0
Japan
State/province [120] 0 0
Fujieda-shi
Country [121] 0 0
Japan
State/province [121] 0 0
Hiroshima-shi
Country [122] 0 0
Korea, Republic of
State/province [122] 0 0
Gyeonggido
Country [123] 0 0
Korea, Republic of
State/province [123] 0 0
Gyeongsangnamdo
Country [124] 0 0
Korea, Republic of
State/province [124] 0 0
Cheongju
Country [125] 0 0
Korea, Republic of
State/province [125] 0 0
Incheon
Country [126] 0 0
Korea, Republic of
State/province [126] 0 0
Jeonnam
Country [127] 0 0
Korea, Republic of
State/province [127] 0 0
Seoul
Country [128] 0 0
Netherlands
State/province [128] 0 0
Noord-Holland
Country [129] 0 0
Netherlands
State/province [129] 0 0
Amersfoort
Country [130] 0 0
Netherlands
State/province [130] 0 0
Harderwijk
Country [131] 0 0
Poland
State/province [131] 0 0
Lodzkie
Country [132] 0 0
Poland
State/province [132] 0 0
Mazowieckie
Country [133] 0 0
Poland
State/province [133] 0 0
Podkarpackie
Country [134] 0 0
Poland
State/province [134] 0 0
Wielkopolskie
Country [135] 0 0
Poland
State/province [135] 0 0
Zachodniopomorskie
Country [136] 0 0
Puerto Rico
State/province [136] 0 0
San Juan
Country [137] 0 0
Romania
State/province [137] 0 0
Dolj
Country [138] 0 0
Romania
State/province [138] 0 0
Prahova
Country [139] 0 0
Romania
State/province [139] 0 0
Bucharest
Country [140] 0 0
Romania
State/province [140] 0 0
Cluj Napoca
Country [141] 0 0
Romania
State/province [141] 0 0
Timisoara
Country [142] 0 0
Russian Federation
State/province [142] 0 0
Krasnoyarskiy Kray
Country [143] 0 0
Russian Federation
State/province [143] 0 0
Novosibirskaya Oblast
Country [144] 0 0
Russian Federation
State/province [144] 0 0
Sankt-Peterburg
Country [145] 0 0
Russian Federation
State/province [145] 0 0
Tatarstan, Respublika
Country [146] 0 0
Russian Federation
State/province [146] 0 0
Volgogradskaya Oblast
Country [147] 0 0
Russian Federation
State/province [147] 0 0
Arkhangelsk
Country [148] 0 0
Russian Federation
State/province [148] 0 0
Chelyabinsk
Country [149] 0 0
Russian Federation
State/province [149] 0 0
Kostroma
Country [150] 0 0
Russian Federation
State/province [150] 0 0
Moscow
Country [151] 0 0
Russian Federation
State/province [151] 0 0
Obninsk
Country [152] 0 0
Russian Federation
State/province [152] 0 0
Omsk
Country [153] 0 0
Russian Federation
State/province [153] 0 0
Pushkin
Country [154] 0 0
Russian Federation
State/province [154] 0 0
Pyatigorsk
Country [155] 0 0
Russian Federation
State/province [155] 0 0
St. Petersburg
Country [156] 0 0
Spain
State/province [156] 0 0
A Coruna
Country [157] 0 0
Spain
State/province [157] 0 0
Barcelona
Country [158] 0 0
Spain
State/province [158] 0 0
Las Palmas
Country [159] 0 0
Spain
State/province [159] 0 0
Madrid
Country [160] 0 0
Spain
State/province [160] 0 0
Avila
Country [161] 0 0
Spain
State/province [161] 0 0
Malaga
Country [162] 0 0
Spain
State/province [162] 0 0
Sevilla
Country [163] 0 0
Spain
State/province [163] 0 0
Valencia
Country [164] 0 0
Switzerland
State/province [164] 0 0
Basel-Stadt
Country [165] 0 0
Switzerland
State/province [165] 0 0
Zuerich
Country [166] 0 0
Taiwan
State/province [166] 0 0
Kaohsiung
Country [167] 0 0
Taiwan
State/province [167] 0 0
Chia-Yi
Country [168] 0 0
Taiwan
State/province [168] 0 0
New Taipei City
Country [169] 0 0
Taiwan
State/province [169] 0 0
Taichung
Country [170] 0 0
Taiwan
State/province [170] 0 0
Tainan
Country [171] 0 0
Taiwan
State/province [171] 0 0
Taipei City
Country [172] 0 0
Taiwan
State/province [172] 0 0
Taipei
Country [173] 0 0
Taiwan
State/province [173] 0 0
Taoyuan City
Country [174] 0 0
Turkey
State/province [174] 0 0
Adana
Country [175] 0 0
Turkey
State/province [175] 0 0
Ankara
Country [176] 0 0
Turkey
State/province [176] 0 0
Antalya
Country [177] 0 0
Turkey
State/province [177] 0 0
Edirne, Istanbul
Country [178] 0 0
Turkey
State/province [178] 0 0
Istanbul
Country [179] 0 0
Turkey
State/province [179] 0 0
Izmir
Country [180] 0 0
United Kingdom
State/province [180] 0 0
London, City Of
Country [181] 0 0
United Kingdom
State/province [181] 0 0
Nottinghamshire
Country [182] 0 0
United Kingdom
State/province [182] 0 0
Oxfordshire
Country [183] 0 0
United Kingdom
State/province [183] 0 0
Birmingham
Country [184] 0 0
United Kingdom
State/province [184] 0 0
London

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
AbbVie
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This study is designed to identify the target Non-Small Cell Lung Cancer (NSCLC)
population(s) that overexpress c-Met (c-Met+) best suited for telisotuzumab vedotin therapy
in the second line or third line setting (Stage 1) and then to expand the group(s) to further
evaluate efficacy in the selected population(s) (Stage 2). After the Stage 2 global
enrollment is completed, an additional cohort at an alternate dose level will evaluate the
safety and efficacy of telisotuzumab vedotin (Stage 3).
Trial website
https://clinicaltrials.gov/ct2/show/NCT03539536
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
ABBVIE INC.
Address 0 0
AbbVie
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT03539536